(CYTK) |
| 0 (0%) 01-13 19:30 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 70.98 |
| Resistance 1: | 66.35 |
| Pivot price: | 63.31 |
| Support 1: | 58.85 |
| Support 2: | 48.96 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | -563280000.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 539.153 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -8.00 |
| Return on Assets (ttm) | 613.4 |
| Return on Equity (ttm) | -24.9 |
Company news
Mon, 12 Jan 2026
CYTK: Mycorrhiza launches with strong clinical data, targeting rapid growth and major market expansion - TradingView — Track All Markets
Mon, 12 Jan 2026
A Look At Cytokinetics (CYTK) Valuation As Shareholder Investigation Raises Governance Questions - simplywall.st
Mon, 12 Jan 2026
Cytokinetics, Incorporated (CYTK) Stock Analysis: A Biotech With 41% Upside Potential - DirectorsTalk Interviews
Fri, 09 Jan 2026
Shareholder Probe Into Aficamten FDA Disclosures Might Change The Case For Investing In Cytokinetics (CYTK) - simplywall.st
Thu, 08 Jan 2026
How Aficamten REMS Disclosure Probe Will Impact Cytokinetics (CYTK) Investors - Yahoo Finance
Mon, 22 Dec 2025
RBC Capital Maintains Cytokinetics (CYTK) Outperform Recommendation - Nasdaq
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
